45. Sternfeld T, Tischleder A, Schuster M, Bogner JR (2009) Mitochondrial membrane potential and apoptosis of blood mononuclear cells in untreated HIV-1 infected patients. HIV Med 10: 512–519. 46. Romani B, Engelbrecht S (2009) Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol 90: 1795–1805. 47. Fausther-Bovendo H, Vieillard V, Sagan S, Bismuth G, Debre P (2010) HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway. PLoS Pathog 6: e1000975. 48. Jolly C, Sattentau QJ (2007) Regulated secretion from CD4+ T cells. Trends Immunol 28: 474–481. 49. Herbein G, Gras G, Khan KA, Abbas W (2010) Macrophage signaling in HIV-1 infection. Retrovirology 7: 34. 50. Klatt NR, Silvestri G (2012) CD4+ T Cells and HIV: A Paradoxical Pas de Deux. Sci Transl Med 4: 123ps124. 51. Muratori C, Cavallin LE, Kratzel K, Tinari A, De Milito A, et al. (2009) Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe 6: 218–230. 52. Lenassi M, Cagney G, Liao M, Vaupotic T, Bartholomeeusen K, et al. (2010) HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 11: 110–122. 53. Sun G, Rossi JJ (2011) MicroRNAs and their potential involvement in HIV infection. Trends Pharmacol Sci 32: 675–681. 54. Xu W, Santini PA, Sullivan JS, He B, Shan M, et al. (2009) HIV-1 evades virus- specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 10: 1008–1017. 55. Lee HC, Wei YH (2005) Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int J Biochem Cell Biol 37: 822–834. 56. Castanier C, Garcin D, Vazquez A, Arnoult D (2010) Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway. EMBO reports 11: 133–138. 57. Berg RK, Melchjorsen J, Rintahaka J, Diget E, Soby S, et al. (2012) Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. PLoS One 7: e29291. 58. Elbim C, Pillet S, Prevost MH, Preira A, Girard PM, et al. (1999) Redox and activation status of monocytes from human immunodeficiency virus-infected patients: relationship with viral load. J Virol 73: 4561–4566. 59. Kadiu I, Wang T, Schlautman JD, Dubrovsky L, Ciborowski P, et al. (2009) HIV-1 transforms the monocyte plasma membrane proteome. Cellular Immunology 258: 44–58. 60. Robinson JM (2009) Phagocytic leukocytes and reactive oxygen species. Histochem Cell Biol 131: 465–469. 61. Reiss M, Roos D (1978) Differences in oxygen metabolism of phagocytosing monocytes and neutrophils. J Clin Invest 61: 480–488. 62. Nakamura H, Masutani H, Yodoi J (2002) Redox imbalance and its control in HIV infection. Antioxid Redox Signal 4: 455–464. 63. Stehbens WE (2004) Oxidative stress in viral hepatitis and AIDS. Exp Mol Pathol 77: 121–132. 64. Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, et al. (2005) Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 40: 565–572. 65. McComsey GA, Kang M, Ross AC, Lebrecht D, Livingston E, et al. (2008) Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials 9: 126–136. 66. Cossarizza A, Riva A, Pinti M, Ammannato S, Fedeli P, et al. (2003) Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther 8: 315–321. 67. Montaner JS, Cote HC, Harris M, Hogg RS, Yip B, et al. (2003) Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr 34 Suppl 1: S85–90. 68. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, et al. (2006) In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 50: 3824–3832. 69. Maagaard A, Kvale D (2009) Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? Journal of Antimicrobial Chemotherapy 64: 901–909. 70. Morse CG, Voss JG, Rakocevic G, McLaughlin M, Vinton CL, et al. (2012) HIV Infection and Antiretroviral Therapy Have Divergent Effects on Mitochondria in Adipose Tissue. J Infect Dis 205: 1778–1787. 71. Mukhopadhyay A, Wei B, Zullo SJ, Wood LV, Weiner H (2002) In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome. Mitochondrion 1: 511–518. 72. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH (2002) The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits HIV and ART Effects on PBMC Mitochondria proteasome function and causes apoptosis and radiosensitization in non-HIV- associated human cancer cells. Cancer Res 62: 5230–5235. 73. Piccinini M, Rinaudo MT, Chiapello N, Ricotti E, Baldovino S, et al. (2002) The human 26S proteasome is a target of antiretroviral agents. Aids 16: 693– 700. 74. Groener JB, Seybold U, Vollbrecht T, Bogner JR (2011) Short Communication: Decrease in Mitochondrial Transmembrane Potential in Peripheral Blood Mononuclear Cells of HIV-Uninfected Subjects Undergoing HIV Postexposure Prophylaxis. AIDS Res Hum Retroviruses 27: 969–972. 75. Lopez S, Negredo E, Garrabou G, Puig J, Ruiz L, et al. (2006) Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retroviruses 22: 33–39. 76. Maggiolo F, Roat E, Pinti M, Nasi M, Gibellini L, et al. (2010) Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treat- ment-naive patients. Antivir Ther 15: 51–59. 77. Einsiedel L, Cherry CL, Sheeran FL, Friedhuber A, Wesselingh SL, et al. (2010) Mitochondrial dysfunction in CD4+ lymphocytes from stavudine-treated HIV patients. Mitochondrion 10: 534–539. 78. Petrovas C, Mueller YM, Dimitriou ID, Altork SR, Banerjee A, et al. (2007) Increased mitochondrial mass characterizes the survival defect of HIV-specific CD8(+) T cells. Blood 109: 2505–2513. 79. Caron M, Auclair M, Lagathu C, Lombes A, Walker UA, et al. (2004) The HIV- 1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. Aids 18: 2127–2136. 80. Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, et al. (2010) Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol 160: 2069– 2084. 81. Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, et al. (2009) Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. Journal of Antimicrobial Chemotherapy 63: 1244–1250. 82. Curran A, Ribera E (2011) From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. Expert Opin Drug Saf 10: 389–406. 83. Martin AM, Almeida CA, Cameron P, Purcell AW, Nolan D, et al. (2007) Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. Aids 21: 1233–1244. 84. Danaher RJ, Kaetzel CS, Greenberg RN, Wang C, Bruno ME, et al. (2010) HIV protease inhibitors alter innate immune response signaling to double- stranded RNA in oral epithelial cells: implications for immune reconstitution inflammatory syndrome? Aids 24: 2587–2590. 85. Coleman CM, Wu L (2009) HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6: 51. 86. Le Douce V, Herbein G, Rohr O, Schwartz C (2010) Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 7: 32. 87. Bergamaschi A, Pancino G (2010) Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 7: 31. 88. Kaushik R, Zhu X, Stranska R, Wu Y, Stevenson M (2009) A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe 6: 68–80. 89. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654–657. 90. Whitelaw DM (1972) Observations on human monocyte kinetics after pulse labeling. Cell Tissue Kinet 5: 311–317. 91. Carter CC, McNamara LA, Onafuwa-Nuga A, Shackleton M, Riddell Jt, et al. (2011) HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 9: 223–234. 92. Alexaki A, Wigdahl B (2008) HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog 4: e1000215. 93. Onafuwa-Nuga A, McNamara LA, Collins KL (2010) Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people. Cell Res 20: 1185–1187. 94. Garrabou G, Lo´pez S, More´n C, Mart´ınez E, Fontdevila J, et al. (2011) Mitochondrial damage in adipose tissue of untreated HIV-infected patients. Aids 25: 165–170. 95. Gavegnano C, Schinazi RF (2009) Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother 20: 63–78. 96. Liu X, Ma Q, Zhang F (2010) Therapeutic drug monitoring in highly active antiretroviral therapy. Expert Opin Drug Saf 9: 743–758. 97. Wei YH, Wu SB, Ma YS, Lee HC (2009) Respiratory function decline and DNA mutation in mitochondria, oxidative stress and altered gene expression during aging. Chang Gung Med J 32: 113–132. PLoS ONE | www.plosone.org 13 July 2012 | Volume 7 | Issue 7 | e41129